Patents by Inventor Ding-Quan Qian

Ding-Quan Qian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Imidazotriaines and imidazopyrimidines as kinase inhibitors
    Patent number: 10738052
    Abstract: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: August 11, 2020
    Assignees: INCYTE HOLDINGS CORPORATION, INCYTE CORPORATION
    Inventors: Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
  • Bicyclic heterocycles as FGFR4 inhibitors
    Patent number: 10738048
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: August 11, 2020
    Assignee: Incyte Corporation
    Inventors: Liang Lu, Liangxing Wu, Ding-Quan Qian, Wenqing Yao
  • CYCLOPROPYLAMINES AS LSD1 INHIBITORS
    Publication number: 20200181077
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: November 20, 2019
    Publication date: June 11, 2020
    Applicant: Incyte Corporation
    Inventors: Liangxing Wu, Chunhong He, Ding-Quan Qian, Bo Shen, Wenqing Yao
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20200181126
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: February 4, 2020
    Publication date: June 11, 2020
    Inventors: Liang Lu, Ding-Quan Qian, Liangxing Wu, Wenqing Yao
  • BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
    Publication number: 20200095244
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: September 10, 2019
    Publication date: March 26, 2020
    Inventors: Yaping Sun, Liang Lu, Wenqing Yao, Jincong Zhuo, Liangxing Wu, Meizhong Xu, Ding-Quan Qian, Chunhong He, Fenglei Zhang
  • BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS
    Publication number: 20200010456
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Application
    Filed: August 29, 2019
    Publication date: January 9, 2020
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
  • Cyclopropylamines as LSD1 inhibitors
    Patent number: 10513493
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: December 24, 2019
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Chunhong He, Ding-Quan Qian, Bo Shen, Wenqing Yao
  • Bipyrazole derivatives as JAK inhibitors
    Patent number: 10435392
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: October 8, 2019
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei
  • IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS
    Publication number: 20190292188
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: February 26, 2019
    Publication date: September 26, 2019
    Inventors: Xiaozhao Wang, Pei Gan, Heeoon Han, Taisheng Huang, Matthew S. McCammant, Chao Qi, Ding-Quan Qian, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Fenglei Zhang
  • BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS
    Publication number: 20190284187
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
    Type: Application
    Filed: April 23, 2019
    Publication date: September 19, 2019
    Inventors: Liangxing Wu, Liang Lu, Ding-Quan Qian, Bo Shen, Wenqing Yao
  • BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS
    Publication number: 20190241560
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
    Type: Application
    Filed: January 3, 2019
    Publication date: August 8, 2019
    Inventors: Liang Lu, Liangxing Wu, Ding-Quan Qian, Wenqing Yao
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20190225601
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: April 2, 2019
    Publication date: July 25, 2019
    Inventors: Liangxing Wu, Jingwei Li, Chao Qi, Fenglei Zhang, Zhenwu Li, Wenyu Zhu, Zhiyong Yu, Kaijiong Xiao, Liang Lu, Song Mei, Ding-Quan Qian, Chunhong He, Yingda Ye, Meizhong Xu, Wenqing Yao
  • CYCLOPROPYLAMINES AS LSD1 INHIBITORS
    Publication number: 20190211014
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: November 19, 2018
    Publication date: July 11, 2019
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Ding-Quan Qian, Bo Shen, Xiaozhao Wang, Wenqing Yao, Fenglei Zhang
  • SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
    Publication number: 20190127376
    Abstract: The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: October 5, 2018
    Publication date: May 2, 2019
    Inventors: Liangxing Wu, Colin Zhang, Chunhong He, Yaping Sun, Liang Lu, Ding-Quan Qian, Meizhong Xu, Jincong Zhuo, Wenqing Yao
  • BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
    Publication number: 20190062327
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: July 2, 2018
    Publication date: February 28, 2019
    Inventors: Yaping Sun, Liang Lu, Wenqing Yao, Jincong Zhuo, Liangxing Wu, Meizhong Xu, Ding-Quan Qian, Chunhong He, Fenglei Zhang
  • CYCLOPROPYLAMINES AS LSD1 INHIBITORS
    Publication number: 20190062301
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: May 4, 2018
    Publication date: February 28, 2019
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Leah C. Konkol, Ding-Quan Qian, Bo Shen, Wenqing Yao, Fenglei Zhang
  • Bicyclic heterocycles as FGFR4 inhibitors
    Patent number: 10214528
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: February 26, 2019
    Assignee: Incyte Corporation
    Inventors: Liang Lu, Liangxing Wu, Ding-Quan Qian, Wenqing Yao
  • BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS
    Publication number: 20180312492
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Application
    Filed: February 15, 2018
    Publication date: November 1, 2018
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
  • Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors
    Publication number: 20180282340
    Abstract: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    Type: Application
    Filed: March 20, 2018
    Publication date: October 4, 2018
    Inventors: Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
  • BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS
    Publication number: 20180244672
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
    Type: Application
    Filed: January 18, 2018
    Publication date: August 30, 2018
    Inventors: Liang Lu, Liangxing Wu, Ding-Quan Qian, Wenqing Yao